Research and Markets Release CKD Pipeline Analysis

Research and Markets Release CKD Pipeline Analysis

Research and Markets recently released a report detailing today’s pipeline therapeutic products for chronic kidney disease (CKD). This irreversible renal condition is more common in geriatric patients, as it results from the gradual, permanent loss of kidney function due to conditions such as diabetes, hypertension, and long-term drug use, to name a few. According to the Centers For Disease Control and Prevention (CDC) one in every 10 American adults – more than 20 million – have some level of CKD.

The publisher’s report covers an extensive list of developmental stage drugs indicated for CKD, which are either in the discovery, preclinical, clinical or marketing phase. The products in the report range include small molecules, monoclonal antibodies, stem cell therapies and RNA-based therapeutics, but exclude symptom relief drugs. The report also discusses some of the industry’s most pressing concerns and foci in research for CKD treatments.

This report will prove essential to pharmaceutical and biotechnology companies, academic institutes, researchers, investors, service providers, and other bodies concerned with finding solutions to CKD, as it will provide comprehensive information on currently available licensing and collaborative opportunities on the market.

Some of the companies mentioned include: Angion Biomedica, Astellas Pharma, Astrazeneca, Blr Bio, Eli Lilly & Co, Opko Health Inc, Pfizer, Regulus Therapeutics, Johnson & Johnson, and Vidasyam Inc.

The full Research and Markets report is available for download here.


Read More CKD News

Researchers have found that although patients with chronic kidney disease (CKD) are commonly affected by iron-deficiency anaemia, a randomized clinical trial (REVOKE) demonstrated evidence that intravenous iron therapy may cause serious adverse events. In the trial, patients treated with intravenous iron had more adverse events than patients treated with oral iron and showed no statistical signs of improved benefit, leading to early termination of the trial.

“For now, oral iron seems to be a safer approach when confronted with iron-deficiency anaemia in patients with CKD,” said Dr. Rajiv Agarwal, lead researcher on the trial, in a research highlight from Nature Reviews Nephrology. “A larger randomized trial to establish the safety of intravenous iron should now be mandated by the FDA.”

Leave a Comment

Your email address will not be published. Required fields are marked *